

Temozolomide

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.

The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

Rejected

General description

INN

Temozolomide

ATC codes

[L01AX03](#)

Medicine type

Chemical agent

EML status history

Application rejected in 2025 ([TRS 1064](#)) for [Ewing sarcoma of bone and articular cartilage of unspecified sites](#)

Application rejected in 2025 ([TRS 1064](#)) for [Other specified gliomas of brain](#)

Application rejected in 2025 ([TRS 1064](#)) for [Neuroblastoma, NOS](#)

Application rejected in 2025 ([TRS 1064](#)) for [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Wikipedia

[Temozolomide](#)

DrugBank

[Temozolomide](#)

Recommendations

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 100 mg in vial powder for injection
- Oral > Solid > capsule: 5 mg; 20 mg; 100 mg; 140 mg; 180 mg; 250 mg

Indications

[Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Other specified gliomas of brain](#) [Neuroblastoma, NOS](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)